Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD): -Correlation with neurophysiological parameters-

Neurophysiologie Clinique

Volumn 34, Issue 2, 2004, Pages 81-89

  Freye, E ^a,d   Levy, J V ^b   Partecke, L ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c Jewish Hospital   (Germany)

^d NONE   (Germany)

Author keywords

Back pain; D sintoxication; Douleur lombaire; Gabapentin; Gabapentine; Mesure de la douleur; Opo des; Pain measurement; Potentiels voqu s somesth siques, PES; Rapid opiate detoxification; Somatosensory evoked potentials (SEP)

Indexed keywords

ANTINOCICEPTIVE AGENT; CLONIDINE; GABAPENTIN; NALTREXONE; OPIATE; PROPOFOL; SOMATOSTATIN;

ADULT; AMPLITUDE MODULATION; ANESTHESIA; ARTICLE; ARTIFICIAL VENTILATION; BACKACHE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENTEROPATHY; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTESTINE MOTILITY; LATENT PERIOD; LONG TERM CARE; MALE; NOCICEPTIVE STIMULATION; OPIATE ADDICTION; PAIN ASSESSMENT; PAIN THRESHOLD; PATIENT COMPLIANCE; QUANTITATIVE ANALYSIS; RESTLESS LEGS SYNDROME; RESTLESSNESS; SYMPATHETIC TONE; SYMPTOMATOLOGY;

ACETIC ACIDS; ADULT; AMINES; ANESTHESIA; ANESTHETICS, INTRAVENOUS; CYCLOHEXANECARBOXYLIC ACIDS; ELECTRIC STIMULATION; EVOKED POTENTIALS, SOMATOSENSORY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEROIN DEPENDENCE; HORMONE ANTAGONISTS; HUMANS; MAGNESIUM; MALE; MEDIAN NERVE; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; POTASSIUM; PROPOFOL; RESTLESS LEGS SYNDROME; SOMATOSTATIN; SUBSTANCE WITHDRAWAL SYNDROME; WATER-ELECTROLYTE BALANCE;

EID: 2342561868     PISSN: 09877053     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neucli.2004.02.002     Document Type: Article

References (45)

1. Loimer N., Schmid R.W., Presslich O., Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res. 23:1989;81-86
2. Loimer N., Lenz K., Schmid R.W., Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenence of patients addicted to opiates. Am J Psychiat. 148:(7):1991;933-935
3. Götz J., Partecke L. Katamnestische Entwicklung Opiatabhängiger nach Naltrexon-induziertem Entzug, naltrexongestützter Rückfallprophylaxe und ambulanter psychosotzialer Nachsorge. Suchttherapie. 1:2000;166-172
4. Goldstein D.B., Goldstein A. Possible role of enzyme inhibition and repression in drug tolerance and addiction. Biochem Pharmac. 8:1961;48-53
5. Brown J.P., Boden P., Singh L., Gee N.S. Mechanims of action of gabapentin. Rev Contemp Pharmacother. 7:1996;203-214
6. Field M.J., Oles R.J., Lewis A.S., McVlerary S., Hughes J., Singh L. Gabapentin (neurontin) and S(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 121:1997;1513-1522
7. Mellik G.A., Larry D.O., Mellik B. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 78:1997;98-105
8. Rosner H., Rubin L., Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 12:1996;56-58
9. Glen J.B. The development of "Diprifusor": a TCI systen for propofol. Anaesthesia. S3:1998;13-21
10. Gold M.S., Pottash A.C., Sweeney D.R., Kleber H.D. Opiate withdrawal using clonidin. A safe, effective, and rapid nonopiate treatment. JAMA. 243:1980;343-348
11. Charney D.S., Heninger G.R., Kleber H.D. The combined use of clonidine and naltrexone a a rapid, safe, and effective treatement of abrupt withdrawal from methadone. Am J Psychiat. 143:(7):1986;831-837
12. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 21:(3):1988;253-259
13. Vining D.H., Kosten T.R., Kleber H.D. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict. 63:1988;567-575
14. Kleber H.D., Topazian M., Gaspari J., Riordan C.E., Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 13:(1, 2):1987;1-17
15. Kienbaum P., Thürauf N., Michel M.C., Scherbaum N., Gaspar M., Peters J. Profound increase in epinephrine in plasma and cardiovascular stimulation after μ-opiate receptor blockade in opiate addicted patients during barbiturate-induced anesthesia for acute detoxyfication. Anesthesiology. 88:1998;1154-1161
16. Ghignone M. Effects of clonidine on narcotic requirements and hemodynamic response during induction of fenanyl anesthesia and endotracheal intubation. Anesthesiology. 67:1987;3-10
17. Jenkins S.A. Somatostatin and octreotide. 1996;Medimedia Asia, Hong Kong
18. North R.A., Williams J.T. Enkephalines inhibit fireing of myenteric neurons. Nature. 246:1975;460
19. Takeda T., Taniyama K., Baba S., Tanaka C. Putative mechanisms involved in excitatory and inhibitory effects of somatostatin on intestinal motility. Am J Physiol. 257:1989;G 532-G 538
20. Williams J., North R.A. Inhibition of firering of myenteric neurones by somatostatin. Brain Res. 155:1978;165-168
21. Kreis G.J. Physiological role of somatostatin in the digestive tract: gastric secretion, intestinal absorption, and motility. Scand J Gastroenterol. 21:1986;47-53
22. Jasper H.H. The ten twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol. 10:1958;371-375
23. Chapmann C.R., Chen A.C.N., Harkins S.W. Brain evoked potentials as correlates of laboratory pain: A review and perspective. Bonica J.J., Liebeskind J.C., Albe-Fessard D.G. Advances in Pain Research and Therapy. 1979;791-803 Raven Press, New York
24. Foltz E.L., White L.E. Pain "relief" by frontal cingulotomy. J Neurosurg. 19:1962;89-100
25. Freeman W., Watts J.W. Pain mechnanisms and the frontal lobes: A study of prefrontal lobotomy for intractable pain. Ann Intern Med. 28:1948;747-754
26. Friedman D.P., Murray E.A. Thalamic connectivity of the second somatosensory area and neighboring somatosensory fields of the lateral sulcus of the Macaque. J Comp Neurol. 252:1986;348-373
27. Kenshalo D.R. Jr, Isensee O. Responses of primates SI cortical neurons to noxious stimuli. J Neurophysiol. 50:1983;1479-1496
28. Guilbaud G., Benoist J.M., Levante A., Gautron M., Willer J.C. Primary somatosensory cortex in rats with pain-related behaviors due to peripheral mononeuropathy after moderate ligation of one sciatic nerve: neuronal responsivity to somatic stimulation. Exp Brain Res. 92:1992;227-245
29. Kochs E., Treede R.D., Schulte am Esch J., Bromm B. Modulation of pain-related somatosensory evoked potentials by general anesthesia. Anesth Analg. 71:1990;225-2230
30. Freye E., Hartung E., Schenk G.K. Somatosensory-evoked potentials during block of surgical stimulation with propofol. Br J Anaesth. 63:1989;357-359
31. Chapmann C.R., Hill H.F., Saeger L., Gavrin J. Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain. Pain. 43:1990;47-55
32. Buchsbaum M.S., Davis G.C., Coppola R., Naber D. Opiate pharmacology and individual differences. II. Somatosensory evoked potentials. Pain. 10:1981;367-377
33. Bromm N.B., Herrmann W.M., Scharein E. Zwei effektive Analgetika im Wirkungsvergleich. -Experimentelle Studie Tramadol versus Tilidin/Naloxon-. Fortschr Med. 17:1989;385-389
34. Pathak K.S., Brown R.H., Cascorbi H.F., Nash C.L. Effects of fentanyl and morphine on intraoperative somatosensory cortical-evoked potentials. Anesth Analg. 63:1984;833-837
35. Loughnan B.L., Sebel P.S., Thomas D., Rutherford C.F., Rogers H. Evoked potentials following diazepam or fentanyl. Anaesthesia. 42:1987;196-198
36. Koht A., Schuetz W., Schmidt G., Schramm J., Watanabe E. Effects of etomidate, midazolam, and thiopental on median nerve somatosensory evoked potentials and the additive effects of fentanyl and nitrous oxide. Anesth Analg. 67:1988;435-441
37. Hill D.R., Suman-Chauhan N., Woodruff G.N. Localisation of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol. 244:1993;303-309
38. Eide W.K. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain. 4:2000;5-17
39. Klepstad P., Maurset A., Moberg E.R., Oye I. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol. 187:1990;513-518
40. Mayer D.J., Mao J., Price D.D. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain. 61:1995;365-374
41. Paronis C.A., Holtzman S.G. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther. 262:1992;1-9
42. Tiseo P.J., Cheng J., Pasternak G.W., Inturrisi C.E. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J Pharmacol Exp Ther. 268:1994;195-201
43. Sandyk R., Fisher H. Serotonin in involuntary movement disorders. Intern J Neuroscience. 42:1988;185-205
44. Allison T., McCarthy G., Wood C.C. The relationship between human long-latency somatosensory evoked potentials recorded from the cortical surface and from the scalp. Electroencephalogr Clin Neurophysiol. 84:1992;301-314
45. Garcia-Larrea L., Frot M., Valeriani M. Brain generators of human laser-evoked potentials. From dipoles to functional significance. Neurophysiol Clin. 6:2003;279-292